Curis Inc(CRIS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:51 PM ET (Korea 9/12 08:51)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -14.29 | Insider Own | 17.07% | Shs Outstand | 1.9M | Perf Week | -17.52% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 87.24% | Insider Trans | 2.88% | Shs Float | 1.7M | Perf Month | -32.34% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -2.67 | Inst Own | 32.08% | Short Float | 9.72% | Perf Quarter | -86.76% |
| Income | -0.02B | P/S | 0.55 | EPS this Y | -306.38% | Inst Trans | -8.46% | Short Ratio | 0.57 | Perf Half Y | -94.41% |
| Sales | 0.00B | P/B | 0.47 | EPS next 5Y | 15.9% | ROA | -87.76% | Short Interest | 0.17M | Perf YTD | -94.28% |
| Book/sh | 2.41 | P/C | 0.42 | EPS past 3/5Y | 63.8% 45.78% | ROE | -693.93% | 52W High | -97.1% ($39.00) | Perf Year | -96.9% |
| Cash/sh | 2.69 | P/FCF | - | Sales past 3/5Y | -2.42% -2.71% | ROIC | -450.54% | 52W Low | 1.8% ($1.11) | Perf 3Y | -99.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.37% | Gross Margin | 97.71% | Volatility(W/M) | 8.86% 12.68% | Perf 5Y | -99.97% |
| Dividend TTM | - | EV/Sales | -0.52 | Sales Y/Y TTM | -62.17% | Oper. Margin | -833.4% | ATR (14) | 0.27 | Perf 10Y | -99.97% |
| Dividend Ex-Date | - | Quick Ratio | 0.49 | EPS Q/Q | 70.48% | Profit Margin | -490.33% | RSI (14) | 19.1 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.49 | Sales Q/Q | -100% | SMA20 | -23.85% ($1.48) | Beta | 3.07 | Target Price | $42.67 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/07/30 | SMA50 | -66.18% ($3.34) | Rel Volume | 0.44 | Prev Close | $1.16 |
| Employees | 24 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 40.38% -100% | SMA200 | -91.18% ($12.81) | Avg Volume(3M) | 0.29M | Price | $1.13 |
| IPO | 2000/8/1 | Option/Short | No/No | Trades | 553 | Volume | 128,304 | Change | -2.59% |
Company
CRIS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩸 Curis() is a clinical-stage oncology biotech with IRAK4 inhibitor emavusertib (CA-4948) as its core pipeline. The company focuses on hematologic cancers such as acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), and primary central nervous system lymphoma (PCNSL), and generates partial revenue from a royalty on Genentech/Roche's Erivedge.
Over the past 1 year, on the lower side
97% below its 1-year high.
CRIS has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -306.4% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 32.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $2M.
CRIS $2M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is CRIS?
CRIS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRIS?
The market cap of CRIS is approximately $2M, ranking 5,830 within its sector.
What is the 52-week high and low for CRIS?
CRIS has recorded a 52-week high of $39.00 and a low of $1.11.
